composition further comprises a swelling agent.

The dosage form of claim 2 wherein said core includes a solubilizer.

Subjection

20. (Once Amended) The dosage form of claim 2 wherein said drug-containing composition further comprises a solubilizer.

Sub

22. (Once Amended) The dosage form of claim 2 wherein said water-swellable composition includes a solubilizer.

Sub >

25. (Once Amended) The dosage form of claim 2 wherein said drug-containing composition further comprises a fluidizing agent.

Cancel claims 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, and 43.

Cancel claims 46, 47, and 48.

Cancel claims 52, 53, 54 and 55.

B7

57. (Once Amended) The dosage form of claim 2 wherein said low-solubility drug is selected from the group consisting of sildenafil and pharmaceutically acceptable salts of sildenafil.

58. (Once Amended) The dosage form of claim 2 wherein said low-solubility drug is selected from the group consisting of sertraline and pharmaceutically acceptable salts of sertraline.

dru

- 59. (Once Amended) The dosage form of claim 2 wherein said low-solubility drug is the mesylate salt of the drug 4-[3-[4-(2-methylimidazol-1-yl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide hemifumarate.
- 60. (Once Amended) The dosage form of claim 2 wherein said low solubility drug is 5-chloro-1H-indole-2-carboxylic acid[(1S)-benzyl-3-((3R, 4S)-dihydroxypyrrolidin-1-yl-)-(2R)-hydroxy-3-oxypropyl]amide.
  - 61. (Once Amended) The dosage form of claim 2 wherein said low solubility drug

\is 5-(2-(4-(3-benzisothiazolyl)-piperazinyl)ethyl-6-chlorooxindole.

C02.

is carprofen.

63. (Once Amended) The dosage form of claim 2 wherein said drug has a maximum solubility of 20 mg/mL in aqueous solution that has a pH between 1 and 8.

62. (Once Amended) The dosage form of claim 2 wherein said low solubility drug

64. (Once Amended) solubility drug.

The dosage form of claim 2 wherein said drug is a low-

65. (Once Amended)

The dosage form of claim 2 wherein said drug is

substantially water insoluble.

66. (Once Amended) The dosage form of claim 2 wherein said drug is sparingly water soluble.

67. (Once Amended) The dosage form of claim 2 wherein said coating has a water flux (40/75) of at least 1.0 x 10<sup>-3</sup> gm/cm<sup>2</sup>-hr.

69. (Once Amended) The dosage form of claim 2 wherein said coating comprises a hydrophilic cellulosic polymer.

B8 Sub>

74. (Once Amended) The dosage form of claim 2 wherein said coating is formed from a solution having a weight ratio of cellulose acetate to polyethylene glycol of from 9:1 to 6.5:3.5.

75. (Once Amended) The dosage form of claim 2 wherein said coating is formed from a solution having a water concentration of greater than 4 wt%.

dez Pd

77. (Once Amended) The dosage form of claim 2 wherein said coating is formed from a solution having a water concentration of greater than 15 wt%.

79. (Once Amended) The dosage form of claim 2 wherein said coating includes at least a pore former.

Cancel claims 82, 83, 84, 85, 86, and 87.

B 11

88. (Once Amended) The dosage form of claim 2 wherein said coating is porous and is formed from a homogeneous solution comprising a solvent, a hydrophilic cellulosic polymer, and a non-solvent.

B12

95. (Once Amended) The dosage form of claim 2 wherein said coating is porous with a dry-state density of less than 8.9 times that of the same coating material in nonporous form.

Cancel claims 98, 99, and 100.

B13

101.(Once Amended) The dosage form of claim 2 wherein said coating has a mass of from 3 to 30 wt% of said core.

Cancel claim 102.

B14

103. (Once Amended) The dosage form of claim 2 wherein, following introduction of said dosage form to a use environment, no more than 50 wt% of said drug is released to said use environment within 2 hours and at least 60 wt% to said use environment is released within 12 hours.

104. (Once Amended) The dosage form of claim 2 wherein, following introduction of said dosage form to a use environment, at least 60 wt% of said drug is released to said use environment within 12 hours.

105. (Once Amended) The dosage form of claim 2 wherein, following introduction of said dosage form to a use environment, at least about 70 wt% of said drug is released to said use environment within about 12 hours.

106. (Once Amended) The dosage form of claim 2 wherein, following introduction of said dosage form to a use environment, at least 80 wt% of said drug is released to said use environment within 24 hours.

107. (Once Amended) The dosage form of claim 2 wherein, following introduction of said dosage form to a use environment, at least 90 wt% of said drug is released to said use environment within 24 hours.